Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
Status:
Withdrawn
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether daratumumab, a drug that eliminates
antibody-producing plasma cells, can effectively lower the level of preformed antibodies in
patients awaiting heart transplantation. These preformed antibodies limit the number of donor
hearts that are compatible for the patients. If daratumumab can effectively remove preformed,
donor-specific antibodies, then highly allosensitized patients will have more compatible
hearts available to them, potentially decreasing transplant waitlist time and reducing
mortality.